NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

AVBP

ArriVent BioPharma Inc

May 12 • 04:00PM ET

19.99

Dollar change -0.16
Percentage change -0.79	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN SRPT VRTX REGN MRNA BIIB GILD IONS NBIX BLUE

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA IWN IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.77	Insider Own	42.87%	Shs Outstand	34.04M	Perf Week	-3.94%
Market Cap	680.56M	Forward P/E	-	EPS next Y	-3.56	Insider Trans	0.00%	Shs Float	19.45M	Perf Month	18.56%
Income	-127.46M	PEG	-	EPS next Q	-0.67	Inst Own	58.90%	Short Float	27.58%	Perf Quarter	-25.72%
Sales	0.00M	P/S	-	EPS this Y	-30.21%	Inst Trans	17.32%	Short Ratio	26.92	Perf Half Y	-42.74%
Book/sh	5.95	P/B	3.36	EPS next Y	-6.75%	ROA	-46.92%	Short Interest	5.36M	Perf Year	15.15%
Cash/sh	5.17	P/C	3.87	EPS next 5Y	4.14%	ROE	-49.00%	52W Range	15.47 - 36.37	Perf YTD	-24.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-62.93%	52W High	-45.04%	Beta	1.47
Dividend TTM	-	Quick Ratio	14.34	Sales past 5Y	0.00%	Gross Margin	-	52W Low	29.22%	ATR (14)	1.32
Dividend Ex-Date	-	Current Ratio	14.34	EPS Y/Y TTM	-69.52%	Oper. Margin	-	RSI (14)	49.76	Volatility	8.33% 6.44%
Employees	52	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	39.29
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-265.27%	Payout	-	Rel Volume	1.21	Prev Close	20.15
Sales Surprise	-	EPS Surprise	-186.14%	Sales Q/Q	-	Earnings	May 12 BMO	Avg Volume	199.29K	Price	19.99
SMA20	-0.45%	SMA50	1.14%	SMA200	-19.92%	Trades		Volume	241,124	Change	-0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-25	Initiated	B. Riley Securities	Buy	$37
Mar-10-25	Initiated	Guggenheim	Buy	$45
Jul-22-24	Initiated	Oppenheimer	Outperform	$35
Apr-30-24	Initiated	H.C. Wainwright	Buy	$25
Feb-20-24	Initiated	Jefferies	Buy	$35
Feb-20-24	Initiated	Goldman	Buy	$27
Feb-20-24	Initiated	Citigroup	Buy	$30

May-12-25 08:00AM	ArriVent BioPharma Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-28-25 08:00AM	ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Mar-19-25 04:23PM	ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts (Insider Monkey)
Mar-03-25 07:00AM	ArriVent BioPharma Reports Full Year 2024 Financial Results (GlobeNewswire) -6.69%
Jan-23-25 07:05AM	ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright (TipRanks)
05:00AM	Loading…
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive) +5.22%
Jan-21-25 07:00PM	ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers (GlobeNewswire)
Nov-14-24 08:00AM	ArriVent BioPharma Reports Third Quarter 2024 Financial Results (GlobeNewswire) -11.86%
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc (GuruFocus.com)
Sep-09-24 12:05PM	ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer (GlobeNewswire)
Aug-19-24 09:55AM	Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
Aug-14-24 09:54PM	AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	ArriVent BioPharma Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 08:00AM	ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer (GlobeNewswire)
Jun-05-24 07:00AM	ArriVent Announces a Multi-Target ADC Collaboration with Alphamab (GlobeNewswire)
04:05PM	Loading…
May-16-24 04:05PM	ArriVent Appoints John Hohneker, M.D., to its Board of Directors (GlobeNewswire)
May-08-24 12:54PM	AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	ArriVent BioPharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 04:05PM	ArriVent Appoints Kristine Peterson to its Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	ArriVent BioPharma Reports Full Year 2023 Financial Results (GlobeNewswire)
Feb-05-24 12:59PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More (Insider Monkey)
Jan-25-24 09:30PM	ArriVent Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on identifying, licensing and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaChapelle Robin	Chief Operating Officer	Sep 19 '24	Option Exercise	3.28	27,566	90,481	124,583	Sep 23 06:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVBP

ArriVent BioPharma Inc

Upgrade your FINVIZ experience